AR068144A1 - Administracion subcutanea de alfa-galactosidasa a - Google Patents
Administracion subcutanea de alfa-galactosidasa aInfo
- Publication number
- AR068144A1 AR068144A1 ARP080103780A ARP080103780A AR068144A1 AR 068144 A1 AR068144 A1 AR 068144A1 AR P080103780 A ARP080103780 A AR P080103780A AR P080103780 A ARP080103780 A AR P080103780A AR 068144 A1 AR068144 A1 AR 068144A1
- Authority
- AR
- Argentina
- Prior art keywords
- alpha
- galactosidase
- gal
- cell
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Métodos para administrar alfa-galactosidase A para el tratamiento de las deficiencias de alfa-galactosidasa A que incluye la enfermedad de Fabri. Reivindicacion 1: Una composicion que comprende de aproximadamente 1 mg/ml a aproximadamente 60 mg/ml de alfa-Gal A, de aproximadamente 2% a aproximadamente 10% (p/v) de carbohidrato, de aproximadamente 5 mM a aproximadamente 10 mM de citrato, hasta 3% (v/v) de excipiente, de aproximadamente 0,05% a aproximadamente 0,5% (v/v) de tensioactivo, y que tiene un pH de 6,0. Reivindicacion 2: La composicion de la reivindicacion 1, en donde el carbohidrato es sacarosa. Reivindicacion 3: La composicion de la reivindicacion 1, en donde el excipiente es glicerol. Reivindicacion 16: El método de cualquiera de las reivindicaciones 11 - 14, en donde alfa-Gal A es alfa-Gal A aislada manipulada genéticamente. Reivindicacion 17: El método de la reivindicacion 16, en donde la alfa-Gal A manipulada genéticamente se produce en una célula humana, una célula de levadura, una célula bacteriana, una célula de insecto o una célula vegetal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96672207P | 2007-08-29 | 2007-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR068144A1 true AR068144A1 (es) | 2009-11-04 |
Family
ID=40230079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103780A AR068144A1 (es) | 2007-08-29 | 2008-08-29 | Administracion subcutanea de alfa-galactosidasa a |
Country Status (4)
Country | Link |
---|---|
US (3) | US20100291060A1 (es) |
EP (1) | EP2185187A1 (es) |
AR (1) | AR068144A1 (es) |
WO (1) | WO2009032171A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE429927T1 (de) | 2000-02-04 | 2009-05-15 | Children S Hospital Res Founda | Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten |
SI2561069T1 (sl) | 2010-04-23 | 2017-07-31 | Alexion Pharmaceuticals, Inc. | Encim za bolezen lizosomskega shranjevanja |
SG10201507199UA (en) | 2010-09-09 | 2015-10-29 | Synageva Biopharma Corp | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
KR20140006037A (ko) | 2011-02-15 | 2014-01-15 | 시나게바 바이오파르마, 코포레이션 | 리소좀의 산 리파제 결핍을 치료하는 방법들 |
US20140219986A1 (en) | 2011-03-11 | 2014-08-07 | Amicus Therapeutics ,Inc. | Dosing regimens for the treatment of fabry disease |
WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
US9907856B2 (en) | 2013-07-08 | 2018-03-06 | The Regents Of The University Of California | Carboxymethylcellulose-peptide conjugates and methods for using the same |
US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179023A (en) * | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
EP2361631A1 (en) * | 2002-04-25 | 2011-08-31 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
-
2008
- 2008-08-28 EP EP08829620A patent/EP2185187A1/en not_active Withdrawn
- 2008-08-28 WO PCT/US2008/010212 patent/WO2009032171A1/en active Application Filing
- 2008-08-28 US US12/675,591 patent/US20100291060A1/en not_active Abandoned
- 2008-08-29 AR ARP080103780A patent/AR068144A1/es unknown
-
2013
- 2013-05-24 US US13/902,297 patent/US20140037612A1/en not_active Abandoned
-
2015
- 2015-05-01 US US14/702,154 patent/US20150306187A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2009032171A1 (en) | 2009-03-12 |
EP2185187A1 (en) | 2010-05-19 |
US20140037612A1 (en) | 2014-02-06 |
US20150306187A1 (en) | 2015-10-29 |
US20100291060A1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR068144A1 (es) | Administracion subcutanea de alfa-galactosidasa a | |
CY1108769T1 (el) | Αναστολεις της διπεπτιδυλικης πεπτιδασης iv για μειωση του ρυθμου της χρονιας αυξησης βαρους | |
AR070198A1 (es) | Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos | |
AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
ECSP066916A (es) | Vacuna contra estreptococo agalactiae | |
NZ713967A (en) | Compositions and methods for treating gaucher disease | |
JP2010516259A5 (es) | ||
PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
CR9076A (es) | Metodo y materiales para conferir resistencia a las pestes y patogenos de plantas | |
MX2023003051A (es) | Formulaciones que comprenden alfa-glucosidasa acida recombinante. | |
AR051806A1 (es) | Manoproteina totalmente soluble en vino y su aplicacion en la estabilizacion del vino | |
CN102406205A (zh) | 牡蛎多糖果汁饮料 | |
CO2022013167A2 (es) | Composiciones y métodos para tratar o prevenir enfermedades inflamatorias que incluyen diabetes mellitus tipo i y tipo ii y enfermedades de la tiroides | |
CN105101985A (zh) | 用于改善硫酸软骨素的生物利用度的含有硫酸软骨素、蛋白水解酶和巯基化合物的组合物 | |
EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
AR074406A1 (es) | Celulas madre terapeuticas derivadas de monocitos humanos y un metodo para inducir celulas madre terapeuticas derivadas de monocitos humanos | |
CN103735537A (zh) | 一种黄腐酚在制备抑制α-葡萄糖苷酶活性的药物或保健品中的应用 | |
RU2006128323A (ru) | Система доставки биологически активных веществ с помощью ниосом | |
Okolicsanyi et al. | Deconjugation of bilirubin glucuronide by the liver | |
CN102301958A (zh) | 一种半枫荷离体组织培养方法 | |
US20130171263A1 (en) | Snake Powder Extract For Treatment Of Cancer | |
NO20081415L (no) | Fremgangsmate for utforelse av en perkutan koronar intervensjon | |
MD3250G2 (ro) | Metodă de tratament al sindromului cheroto-conjunctivitei sica | |
RU2009142007A (ru) | Способ лечения вазомоторного ринита | |
AR125031A1 (es) | Formas farmacéuticas sólidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |